Knowing When and How to Fight: COVID-19 between Viral Clearance and Immune Tolerance

Ahmad R. H. Utomo

CITO Laboratorium Klinik Semarang, Central Java, Indonesia

INTRODUCTION

Coronavirus disease 2019 or COVID-19 has claimed many lives and globally has not gone unabated. Started in late December 2019, COVID-19 has been described as an unusual pneumonia affecting initially people who had attended and traded in wet animal market in Wuhan. Soon thereafter the causative viral agent has been identified and its genomic sequence has been made public. The RNA virus is named SARS-CoV-2 because its genomic homology to SARS-CoV-1, a beta coronavirus that causes SARS (Severe Acute Respiratory Syndrome) in 2002-2004. Moreover, just like SARS-CoV-1, SARS-CoV-2 also recognizes and binds human ACE2 (Angiotensin Converting Enzyme). Unlike SARS that had been controlled within 8 months after infecting 8,100 people in selected territories, COVID-19 has spread globally within just 5 months infecting 2.6 million people and has overwhelmed health care facilities worldwide and sometimes claimed many lives of professional healthcare workers. As of 29th of June 2020, there are over 10 million laboratory-confirmed cases worldwide with more than 0.5 million deaths.

As the details of COVID19 have continued to be unfolded, this review article aims to provide some key features that make COVID19 unique vis a vis other
coronavirus associated diseases namely SARS and MERS and helps giving an overview of challenges in controlling the disease.

BATTLE PLAN

Imagery of fighting SARS-Cov-2, causative agent of COVID-19 invokes the sight of an all-out immunological war pitting human hosts against invisible invading pathogens. However, immunology also tells us that knowing when and how to fight is key to curb transmission. Moreover, the ultimate outcome of any battle against pathogens is to avoid fatal outcome and to minimize long-term morbidity amongst survivors. Efforts to curb COVID-19 pandemic do require multi-pronged approaches and should have awareness about timing and stages of disease progression. Not only knowing how to clear infection but also how to survive infections. This is where mapping out battle plan is essential to guide concerted effort about when and how to fight.

The battle plans may draw up two scenarios mainly based on enemy movement. First, when the enemy has not reached a shore, gathering intelligence is key. Since COVID-19 outbreak has initiated in China, many countries have formed defensive positions. At this stage, intelligence gathering is critical to address the following questions. What is the causative agent of COVID-19? What does COVID-19 do to the body? How does SARS-CoV-2 spread among the people? How to detect individuals infected with SARS-CoV-2? Moreover, once the enemy has breached defensive lines, the second scenario would implement combinatorial efforts of clearing viral infection and building up immune tolerance. In addition, vulnerable individuals such as those with hypertension, diabetes, obesity and certain heart comorbidities should be paid close attentions for getting worst clinical outcome.

FIRST SCENARIO: Keeping the enemy at Bay

“If you know the enemy and know yourself, you need not fear the result of a hundred battles” (Sun Tzu, The Art of War).

Even though there is already strong association between the presence of viral RNA of SARS-CoV-2 and clinical symptoms of COVID-19 (fever, dry cough, myalgia, malaise, loss of smells, ground glass opacity) formal proof to demonstrate causality is needed. SARS-CoV-1 has been defined as a causative agent of SARS because it has fulfilled Koch Postulate in mouse model expressing human ACE2 (Angiotensin Converting Enzyme) receptors. Fulfillment of Koch Postulate is important to build confidence in development of diagnostic, preventive, and treatment strategies.

A. What is the causative agent of COVID-19?

In case of COVID-19, several laboratories have used many approaches to prove causality of SARS-CoV-2 infection and appearance of the disease. First, transgenic mice that express human ACE2 have been made using transgenic cassette, or gene editing. Adenoviral infection carrying human ACE2 is another strategy to introduce human ACE2, an important receptor required for SARS-CoV-2 entry. Second, transgenic mice expressing human ACE2 have been challenged with SARS-CoV-2 viral particles and the results show many recapitulations of human diseases, Pulmonary edema and massive leucocytes infiltration have been observed consistently in infected human ACE2 transgenic mice. Furthermore, peaks of viral load have been observed and virus particles have been recovered from the infected lungs within few days that mimic human pathophysiology of COVID-19. These phenotypes are not found in wild type mice that do not express human ACE2 in spite of deliberate SARS-CoV-2 infection proving exquisite specificity. These key results fulfill Koch postulate and provide theoretical foundation to design diagnostic strategy, discover novel drugs, and elucidate molecular pathology. Moreover, these ACE2 mice will serve as preclinical models to test putative or novel antiviral drugs and vaccine efficacy.

While SARS-CoV-2 is now firmly established as a causative agent of COVID-19, there was a lingering question “where does it come from”? The zoonotic origin of COVID-19 has been implicated by high genomic homology or 96% identity between SARS-CoV-2 and bat coronavirus. To address many speculations that SARS-CoV-2 was a man-made manipulation, a careful structural genomic analyses of the receptor binding domain (RBD) of Spike SARS-CoV-2 has been performed. The results show that there are many mutations in the Spike RBD of SARS-CoV-2 that diverge from SARS-CoV-1, a coronavirus that causes SARS. In spite of the large genetic divergence, both RBDs from these coronaviruses are able to bind human ACE2. Moreover, several experiments have confirmed these specific binding and demonstrated even higher affinity of SARS-CoV-2 RBD to ACE2 than SARS-CoV-1. Therefore, these genetic and biochemical data has put to rest the possibility of the virus being a man-made creation. Furthermore, many laboratories have continued to search for animal reservoirs of SARS-CoV-2 and explored the possibility of genomic recombination’s either within bat coronaviruses or with other coronaviruses belonging to pangolin or other unidentified animals. These studies may pave better understanding of zoonotic disease evolution and transmission to human.

B. What does SARS-CoV-2 do to the body

COVID-19 patients also show some abnormal immunological and vascular profiles that relate to pathological inflammation and coagulation. Relatively high circulating interleukin-6 (IL-6), high NLR (neutrophils to leucocytes ratio), lymphopenia, presence of radiological ground glass opacity, high d-dimers, thrombocytopenia, and low platelet counts. Recent series of autopsy studies on deceased COVID-19 patients also show high prevalence of fatal pulmonary thromboembolism, diffuse alveolar damage and presence of viral RNA in lung parenchyma. Some studies also suggest cytopathic endothelial damage and abnormal blood vessel formations.

C. Tracking enemy movement (Modes of SARS-CoV-2 transmission)

SARS-CoV-2 has similar characteristics with SARS-CoV-1 and MERS-CoV (causing SARS and MERS,
respectively) in terms of genetic backbone (that is homologous to bat coronaviruses genome), spillover zoonotic infection leading to human to human transmission, and shared clinical symptoms (dry cough, myalgia, fever, gastrointestinal and pulmonary involvements)." However, there are notable differences such as high transmission or Ro reproduction numbers (2.5, 2.4, and 2 for SARS-CoV-2, SARS-CoV-1, MERS-CoV, respectively). Rapid timing to reach peaks of viral load (SARS-CoV-2 takes 3 to 5 days while SARS-CoV-1 7 to 10 days), high affinity to ACE2 receptor (SARS-CoV-2 is 10 times higher than SARS-CoV-1) and SARS-CoV-2 tropism to upper respiratory organs (while SARS-CoV-1 is mostly in lower respiratory organs) (22). Collectively, these unique features make SARS-CoV-2 transmission more difficult to control and consequently more infectious than SARS-CoV-1 and MERS-CoV.

Close examination of spike proteins of SARS-CoV-2 may also explain efficient viral transmission when compared to SARS-CoV-1. Spike proteins contain receptor binding domain (RBD) that is important to bind human proteins that is essential for viral binding and fusion. Spike proteins of SARS-CoV2 has ten times higher affinity to bind human ACE2 receptor than SARS-CoV-1.\(^1\)\(^3\)\(^4\) Further, there is a short insertion of four polybasic amino acids within Spike protein that serve as furin binding sites that allow efficient fusion to human cells.\(^1\)\(^2\)\(^3\)\(^4\) Recent in vitro analysis of SARS-CoV-2 spike protein also demonstrated that G614 variant may infect human cells more efficiently and produce higher numbers of viral particles than D614 variant.\(^5\) The change from Aspartic acid to Glycine at codon 614 may lead to efficient virus to human cell fusion. This result has been proposed to explain the predominance and viral existence of D614 variant in North America and Europe. However, this putative explanation of G614 variant of SARS-CoV-2 rapid transmission does not correlate with COVID-19 severity (26).

SARS-CoV-2 transmission is largely through close contacts when droplets of infected individuals are picked up by other individuals. Other studies suggest that some medical procedures in hospitals may also create aerosols that may carry virus particle in the environments.\(^6\) In public settings, the use of face masks has been highly recommended to prevent transmission. Since SARS-CoV-2 viral load may build up rapidly in upper respiratory organs of individuals with or without mild symptoms, contact tracing is essential and deployment of proper diagnostic is a must. Recently, the prospect of airborne transmission of the virus raise serious issue after the description of viral transmission in a restaurant in Guangzhou and an incident of choir practice in the United States attended by 60 people leaving 33 confirmed cases and 2 deaths.\(^2\)\(^8\)\(^9\) These incidents outline the risk of airborne transmission due to gathering of human activity in enclosed space for hours. In addition to proper diagnostic to halt virus transmission, there are three public health policy models to control COVID-19. First, comprehensive lockdown has been practiced by China in order to halt public mobility for several weeks and discourage viral transmission.\(^2\)\(^0\) Second, massive RTPCR testing has been implemented by South Korea to identify and confirm every possible suspect of SARS-CoV-2 carriers.\(^3\)\(^1\) Lastly, encouragement of public gathering for young people and limiting vulnerable population (elderly population and people with comorbidity) has been enacted in Sweden.\(^3\)\(^2\) The first two models have led to ‘flattening the curve’ where new cases have been haltered. On the other hand, Sweden experience has ended up with highest mortality rates amongst Nordic countries who implemented strict measures of public mobility.\(^3\)\(^3\)\(^3\)\(^4\)

D. How to detect the enemy

Publications of SARS-CoV-2 genome have also prompted global efforts to design RTPCR test and dissemination of RTPCR diagnostic kits.\(^3\)\(^5\)\(^3\)\(^6\)\(^7\) Primary aim of COVID-19 is to break chain of transmission by identifying individuals who are infected with SARS-CoV-2. Individuals with confirmed RTPCR results would be isolated in order to protect population at large from getting infections. Secondly, diagnostics may help to monitor recovery of COVID-19 patients by detecting the presence of viral RNA in the patient bodies.\(^3\)\(^7\) Patients who are in the path of recovery may be tested two times with RTPCR within two days. When the RTPCR results show two negative results in two consecutive days, patients are eligible to be discharged.\(^3\)\(^8\) However, this protocol may be modified in some countries who adopt 3 weeks monitoring of clinical parameters as readout of recovery since shortage of RTPCR may be allocated to perform contact tracing of infected individuals.

There are three steps in COVID-19 diagnosis: preanalytical, analytical, and post analytical steps. To avoid diagnostic inaccuracy, care must be given during pre-analytical step which include specimen collection from ideal anatomical sites, specimen preservations and rapid and robust RNA extractions.\(^3\)\(^9\)\(^4\) Nasopharyngeal and oropharyngeal specimens are usually collected together from suspected individuals who are at risk of contracting the virus due travel history to or from epidemic areas, close contact with confirmed cases of COVID-19, or appearance of symptoms. Recently, saliva may also serve as alternative samplings and has been demonstrated to have similar accuracy to conventional samplings with less risk to healthcare workers.\(^4\) Asymptomatic or pre-symptomatic individuals are also a concern because up to 50% infected individuals do not appear to be sick.\(^4\)\(^2\) Yet, studies have shown that viral loads are high in these individuals rendering transmission is likely.

Specimen preservation especially from remote areas must reach laboratory using proper VTMs and temperatures to prevent viral RNA degradation. Lastly, RNA extraction can become bottleneck in RTPCR procedures especially when there is shortage of RNA extraction reagents due to high demands from laboratory performing high volume testing. Therefore, automated RNA extraction is preferable to obtain consistent results. Alternatively, direct RTPCR protocol has been proposed to skip RNA extraction step and speed up testing procedures.\(^7\)

During analytical step, the choice of methods and analyte is important. Due to backlog of RTPCR testing, some countries have used lateral flow-based antibody testing that has rapid turnaround time, typically completed within 15 minutes and can be performed as...
point of care testing requiring as little as a drop of blood. Although some governments have deployed this tactic, emerging literatures show that rapid antibody testing that seek to detect anti-viral spike proteins of SARS-CoV-2 antibodies may not be appropriate to perform diagnostic due to low sensitivity in early phase of infections, where virus particle is at the highest. During this early phase, infected individuals may transmit the virus to others while they have not developed antibodies against the virus, which typically appear 7 to 14 days after first onset of symptoms. Reported diagnostic sensitivity of lateral flow test during early infection phase is between 20-40%.

In comparison, RTPCR based testing diagnostic sensitivity is between 60-70%. Due to this low sensitivity the use lateral-flow based diagnostics is highly discouraged except in the setting of clinical validation or immunosurveillance studies to estimate the burden of infection within certain community or territory. Semiquantitative reversed transcriptase real time RTPCR is currently a gold standard to detect RNA of SARS-CoV-2. Sample collection must be taken within less than 5 days after first symptoms appear. Most RTPCR primers are targeting ORF1, RdRP, and N genes of SARS-CoV-2 where the mutations in these regions are relatively rare i.e. less than 1%.

E. To isolate source of infections
COVID-19 outbreak in cruise ship Diamond Princess shows the importance of contact tracing and extend RTPCR testing to asymptomatic individuals. Japanese authority reports that at the end of massive RTPCR testing of all passengers and crews demonstrated that asymptomatic individuals contribute up to 50% of total RTPCR confirmed cases. Furthermore, many studies have found risk of viral transmission by asymptomatic individuals to susceptible individuals.

F. To monitor recovery of COVID-19 patients
As disease progresses, majority of COVID-19 patients have shown clinical improvement and demonstrated low to undetectable viral RNA. While some nasopharyngeal swabs of recovering patients are standard methods to monitor viral burdens, some studies suggest performing rectal swab RTPCR. Viable viral particles have been recovered from fecal specimens and support the possibility of fecal oral transmission. Environmental monitoring also shows presence of viral RNA in waste centers and toilets where patients are being treated.

SECOND SCENARIO: Meeting enemy at the gate (viral clearance and/or immune tolerance)
A. Initial phase of infection
Infection of SARS-CoV-2 begins with binding of viral Spike protein to human ACE2 receptor. Upon binding, human serine protease TMPRSS2 cleaves off S1 subunit of viral Spike protein exposing S2 subunit which initiates fusion to host cell membranes leading to invagination and endocytosis. Up to 80% of infected individuals who have either asymptomatic to mild or moderate symptoms, viral infections are cleared early and effectively. Fusion of viral particles and release of viral RNA trigger a series of immune activation namely Pattern Recognition Receptor (PRR) leading to interferons production. Interferon pathway is a major innate immunity defense mechanism to clear viral infection through recruitment of macrophages, neutrophils and natural killer cells. In addition, dying or apoptotic infected cells are phagocytosed by macrophages and initiated the release of pro-inflammatory cytokines such as IL-1, TNF alpha and IL-6 promoting further recruitment of immune cells. Direct uptake of viral particles or indirect by phagocytosis of dying cells by dendritic cells or professional Antigen Presenting Cells (APC) will initiate activation of adaptive immune cells. APC loads and presents epitope (antigenic peptides) of viral particle to T helper cells and activates them. T helper cells then promote differentiation of antibody producing B cells and cytotoxic CD8 T cells. Combination of viral specific antibody production and activation of circulating cytotoxic T cells are important to ward off future infection. Successful control of viral infection is also shown by the declining amount of viral RNA and the appearance of IgG anti SARS-CoV-2.

Majority of individuals who survive the initial phase of infection often show no symptoms or at best mild symptoms requiring no hospitalization. Interestingly, antibody titers against SARS-CoV-2 that are being generated in these individuals for some unknown reasons are low and not sustained at high level, especially when compared to COVID-19 patients with serious conditions. It is not clear whether recovery from infections is determined either from certain level of high plasma neutralizing antibodies or activation of adaptive immunity that is driven by circulating memory T-cells. At this stage, neither viral burden nor neutralizing antibody predict recovery of infections.

There are also some anecdotal reports that individuals who have recovered from COVID-19 remain vulnerable to another infection, although the clinical manifestation is usually mild. Moreover, there is also a need for long term surveillance amongst survivors because there is a risk to develop diabetes, lung fibrosis, and lung cancers. ACE2 is also expressed in pancreatic cells producing insulin and SarS-CoV-2 infection may induce apoptosis and compromise the ability to produce insulin. The appearance of ground glass opacity in the lung may also implicate some degree of inflammation that has long term health consequences such as breathing and promotion of lung tumorigenesis.

Children and individuals with O blood type are having better position to avoid severe COVID-19. Some have suggested that children tend to have “high” level of ACE2 expression which may save them from getting uncontrolled inflammation. Although ACE2 is an essential receptor for SARs-CoV-2 infection, ACE2 is an important enzyme to convert Angiotensin 2 (pro inflammatory and vasoconstrictor) into Angiotensin 1-7 (anti-inflammatory and vasodilator). Therefore, high ACE2 expression actually helps maintain ‘anti inflammation’ milieu as the body attempts to clear viral infections.
In contrast to children, elderly population is particularly susceptible to COVID-19 and has high risk of morbidity and mortality. The expression of ACE2 has been thought to be lower in aging adults than children. Although low ACE2 expression being SARS-CoV-2 obligate receptor may intuitively confer less susceptibility to infection, post-infection actually leads to internalization of surface ACE2 expression leading to aggravation of hypertension and inflammation(60). Old age is also associated with immune-senescence and inflame-aging, a combination leading to inability to clear viral infection effectively. Furthermore, the prevalence of comorbidities such as diabetes, cardiovascular diseases, and hypertension are more common in old age. Blood type O is also found to have the lowest risk of severe infections than other blood type, especially blood type A as demonstrated by clinical study in China and genome wide screening data in Europe (63, 64). The protective effect of type O blood is related to the presence of anti A antibodies which target certain glycosylated antigens. This protective factor is also found during SARS. Heavily glycosylated Spike protein of SARS-CoV-2 like SARS-CoV-1 are needed to bind ACE2 in order to initiate infection. However, anti A antibody targeting glycosylated peptide may also interfere with effective binding of spike to ACE2 hence conferring some protection.

Since pneumonia is one of the COVID-19 hallmarks, underlying respiratory diseases affecting lung physiology such as chronic obstructive pulmonary disease (COPD) and lung cancer are expected to confer high risk of morbidity and/or mortality. Recent study and meta-analysis review indeed confirm the expectation that COVID-19 patients with COPD have poor prognosis than patients without COPD. High fatality rate in COVID-19 patients with lung cancer has been observed recently. Therefore, extra precautionary measures must be placed to protect individuals with lung diseases from contracting COVID-19.

There is another speculation that national programmed of BCG vaccination may protect some community against COVID-19. Northern America and Western Europe who do not mandate BCG vaccination are relatively hard hit compared to some Asian nations who are still running obligatory BCG vaccination. The protective mechanism of previous vaccination against COVID-19 invoke the concept of ‘trained immunity’, where non-specific immunity against unrelated pathogens may induce some resistance to other pathogens (70). However, the role of BCG vaccination has been challenged recently and calls for prospective study to clear up the debates.

B. Second phase of viral infection

For the remaining 20% of infected individuals, viral clearance is either unsuccessful and/or ending up with futile inflammation known as cytokine storms. Like COVID-19 predecessors SARS and MERS, inflammation also triggers pulmonary coagulopathy and occasionally disseminated intravascular coagulation. When SARS-CoV-2 enters the respiratory organs, ACE2 expressing alveolar epithelial cells are the virus main targets. In addition, pulmonary vasculatures that are made up of ACE2 expressing endothelial cells are also susceptible to SARS-CoV-2 infection. Ensuing endothelial damages, pro coagulation thrombins are released and initiate coagulation cascades as shown in high level of d-dimers and low level of platelet counts (thrombocytopenia) which are associated with severe COVID-19 cases and mortality risk. Therefore, when left unchecked, thrombi formation may impede pulmonary blood circulation leading to hypoxia and compromising oxygen exchange.

Studies on severe and critical COVID-19 patients also reveal abnormal immunological reads out. Pro inflammatory IL-6 is found to be elevated and explain high burden of immune infiltration in the lung exacerbating tissue damage. High IL-6 is also consistent with lymphopenia, where there is a drop of circulating lymphocytes. Lymphocytes reduction may be explained by two mechanisms. Lymphocytes may leave circulation to enter alveolar spaces creating tissue damages. Alternatively, SARS-CoV-2 may directly infect and kill lymphocytes through CD147 (77). In spite of having have low level expressions of ACE2, lymphocytes remain sensitive to SARCoV2 infection, because spike proteins of SARS-CoV-2 have 10 times higher affinity to bind Ace2 than SARS-CoV-1.

Therefore, there is a therapeutic challenge for patients who are undergoing the next phase of infection where there is a dangerous liaison between inflammatory self-injury and ongoing viral presence. While high viral burden may predict progression to severe cases of COVID-19, reduction of viral burden in itself may not lead to automatic recovery.

Therefore, aggressive measures to block viral entry or replication may seem futile once the disease has become progressive into severe symptoms. Clinical trials of hydroxychloroquine which aims to block viral entry by increasing pH of the endosome has been shown to be ineffective in severe COVID-19 patients. Acidic endosomes have been thought to be important to assemble viral proteins to produce virions. Although in vitro data suggest successful blocking of SARS-CoV-2 by hydroxychloroquine, WHO SOLIDARITY clinical trial has announced to stop HC arm based on interim analysis demonstrating lack of benefit. Another trial in Brazil also shows unacceptable HC toxicity in severe COVID-19 patients.

Combinations of protease inhibitors Ritonavir and Lopinavir have been used to treat HIV patients. Viral proteases are also required for proper assembly of virus particles. However, recent clinical trial also fails to demonstrate benefit. Lastly, antiviral drug remdesivir, which is an adenosine analogue to interfere with SARS-CoV-2 RDRP enzyme during viral RNA replication also has mixed results. Randomized clinical trial in China fails to show statistically significant benefit of remdesivir (84). However, another RCT has shown that remdesivir may induce some clinical improvement in the preliminary report.

Convalescence plasma (CP) therapy is an example to control viral infection in severe cases of COVID-19. The idea of CP rests on the assumption that individuals who are recovered from COVID-19 may contain levels of neutralizing antibody against SARS-CoV-2 and may
help current patients to control viral burden. CP has been used during SARS with some inconclusive results because SARS itself has been controlled fairly quickly. There are some case reports of few patients with severe COVID-19 who are recovered when given CP. A large retrospective study from China also reports clinical improvement.\textsuperscript{87} However, recent meta-analysis has demonstrated the difficulty to draw conclusion of CP efficacy due to lack of clear results obtained from existing randomized clinical trial.\textsuperscript{88} Recent clinical trial has been discontinued due to difficulty to recruit severe patients as subjects, ironically as a result of successful lockdown.\textsuperscript{89}

Interim analyses of the Chinese RCT shows that there is a consistent reduction of viral burden that is estimated from the Ct value of RT PCR.\textsuperscript{89} Ct values under 15 is generally indicative of high viral burden. Both severe and critical patients receiving CP show consistent reduction of viral burden after treatment. However, this reduction does not associate directly with clinical improvement.\textsuperscript{89} It is not clear whether failure to see CP efficacy is due to lack or insufficient level of neutralizing antibody (Nab) in CP donors. In fact, studies on neutralizing antibody dynamic show that severe COVID-19 patients have higher level of Nab than individuals who have recovered from COVID-19. Therefore, much to be learned to explain why some severe patients do get clinical improvement after CP therapy.

Another innovative approach to block SARS-CoV-2 virus infection is inject soluble recombinant human ACE2.\textsuperscript{90} There are two reasons why this approach may work as supported by recent successful preclinical data on animal model expressing human ACE2. First, the soluble ACE2 may act like decoy and biological sink to attract SARS-CoV-2.\textsuperscript{91} Second, the circulating ACE2 may capture and convert Angiotensin 2 into Ang 1-7. Infection of SARS-CoV-2 may cause downregulation of endogenous ACE2 leading to elevated levels of Ang 2 which promote inflammation.\textsuperscript{92} Injection of soluble ACE2 may control and bring down Ang2.

While antiviral studies have not yield conclusive efficacy to treat COVID-19, drugs to control inflammation and/or maintain physiological function such as blood pressure and blood glucose have shown some benefits.

Controlling inflammation (immune tolerance)

Generally, reducing inflammation in viral infected individuals runs risk of getting secondary bacterial or nosocomial infections. IL-6 is one of the inflammatory cytokines that is consistently upregulated and may serve as predictor of severe COVID-19 cases. Tocilizumab is a monoclonal antibody targeting IL-6 that is currently undergoing clinical trial in severe COVID-19 cases.\textsuperscript{93} BTK inhibitor is another example of repurposing drug that is originally given as anti-cancer drugs. The inhibitor targets the cells that are expressing IL-6 at high levels.\textsuperscript{94}

Recovery Clinical Trial in the United Kingdom shows that Dexamethasone may reduce mortality risk to 30% in severe cases of COVID-19 but not in mild cases (95, 96). Dexamethasone, a well-known anti-inflammatory drug with plethora of side effects may not be an ideal drug but the results show that reducing inflammatory burden is as important as viral clearance.

Controlling coagulation

Pulmonary coagulopathy and occasionally disseminated intravascular coagulation have been observed in COVID-19 patients.\textsuperscript{74,75,98} Autopsy reports also show that the majority of fatal COVID-19 cases have shown abnormal coagulation especially in the lung. However, giving blood thinner or anti-coagulant may also run risk of bleeding. Therefore, timing to give blood thinner must be paid close attention. Several clinical trials are ongoing to see the effect of anti-coagulations.\textsuperscript{97,100}

Controlling blood pressure

Hypertension has been identified as a risk factor associated with severe case of COVID-19.\textsuperscript{101} This is due to generally lack or reduced level of ACE2 expression in hypertensive, diabetic, and some patients with cardiac conditions.\textsuperscript{102} ACE2 is one of the homeostasis regulator of RAS system renin-angiotensin-aldosterone system. Angiotensin 2, a substrate of ACE2 is a potent vasoconstrictor and inducer of inflammations. ACE2 is converting Angiotensin 2 into Angiotensin 1-7 that has opposite effect to Ang2 i.e. vasodilators and anti-inflammation. While hypertensive and diabetic patients’ risk of infection is identical to individuals who have no comorbidities, hypertension and diabetic poses significant risk to get a severe case of COVID-19. Hypertensive and diabetic patients have already risk of being high inflammatory status and prone to undergo cytokine storms.\textsuperscript{102}

Since SARS-CoV-2 binds to ACE2, there are concerns that hypertensive patients may be at risk to have higher susceptibility to be infected when they do not stop consuming hypertension drugs. The concern is based in animal studies where treatments of ACE (angiotensin converting enzyme) inhibitor or ARB (angiotensin receptor blockers) lead to elevated expression of ACE2.\textsuperscript{103,104} However, recent studies show that the consumptions of ACEi and ARB by hypertensive patients are not associated with higher risk of mortality and morbidity than those who do not consume.\textsuperscript{105-107} In one study, anti-hypertensive drug consumption may actually associate with better clinical outcome.\textsuperscript{108} Therefore, whether there is an unintended benefit of ACEi and ARB to improve COVID-19 outcome should be tested in RCT. Meanwhile American Heart Association has recommended patients to continue with their hypertensive medications even when diagnosed with COVID-19.\textsuperscript{109}

Controlling blood glucose

Recent gene expressions study suggest that diabetic patients may have been associated with high level expression of ACE2, receptors for SARS-CoV-2 Spike proteins.\textsuperscript{110} Moreover, hyperglycemia commonly found in diabetic patients may also induce ACE2 expression. Whether elevated ACE2 expression correlates with high burden of SARS-CoV-2 virus remain to be seen. However, diabetic patients do have some inflammation within their vascular system. Therefore, infection of SARS-CoV-2 may exacerbate the already pro-inflammatory and pro coagulatory status in diabetic
patients. Interestingly, COVID-19 patients with diabetes may have higher chance of survival when they are able to control their blood sugar.111

TOWARD END OF A PANDEMIC?
‘The supreme art of war is to subdue the enemy without fighting.’ (Sun Tzu)

Through strict public health policy measures, SARS and MERS have been eliminated in matter of months with much less victims than what COVID-19 has claimed to date. This rapid elimination could also be attributed to high case fatality rate of SARS and MERS ie 10% and 30%, respectively. Therefore, victims who fall ills are relatively easy to be identified and isolated. However, complete elimination of SARS and MERS has left substantial gaps in our knowledge about pathogenic coronavirus behavior. Vaccines against SARS and MERS have not been developed forcing the scientific community to start developing COVID-19 from scratch.

Fortunately, the advance of bioinformatics and speed of Next Generation Sequencing have helped warp-speed the production of modern vaccines such as DNA/RNA vaccines and recombinant antigens that are relatively inexpensive than the traditional approach making vaccine seed using inactivated or weakened virus approach.112,113 However, though initial production of vaccine seeds may take short time, there is a hurdle of testing the efficacy of these variety of vaccines in protecting the population from future infections.

There are several concerns about how to prove vaccine efficacy.114 First, individuals who have mild or asymptomatic COVID-19 and are recovered from COVID-19 do not have sustainable level of antibody.115 Therefore, the putative protection conferred by the vaccines should be described in detail regarding the level and sustainability of neutralizing antibody being generated, the production of mucosal immunity to intercept the virus in respiratory organs and the presence of memory T cells. Secondly, vaccines that produce low or insufficient level of neutralizing antibody may lead to ADE (antibody dependent enhancement) of SARS-CoV-2 infection with worst symptoms. These low levels anti SARS-CoV-2 antibody being produced by poorly validated vaccine forms immune complex with actual virus. These unintentional immune complex formations may illicit violent immune response mediated by Fc gamma receptors of the innate immune cells.115 Moreover, innate immunity would be inadvertently a target of infection themselves compromising the first line of defenses against incoming viruses. Although ADE has been well described in Dengue Hemorrhagic Fever, ADE in SARS-CoV-2 has not been documented. However, ADE remains a theoretical possibility due to the speed of vaccine development which may have risk of overlooking the details of vaccine validation before rolling it out to the population.

CONCLUSIONS
COVID-19 pandemic has taught many lessons regarding our state of knowledge. Apparently neither existing knowledge nor experiences are able to stop the global reach of COVID-19 transmission. Apparently, medical intervention alone is insufficient but must involve social cooperation such as physical distancing and personal hygiene. The relatively high viral burden without necessarily showing symptoms does contribute to the rapid transmission. Therefore, innovation in point-of-care diagnostics is key to identify the enemy as early as possible. The complex inflammatory and coagulation impact of COVID-19 must be understood in detail in order to mount precise treatment and patient stratification.99 Complete biomarkers profiling using comprehensive molecular tools could be important to predict patients who are most likely to recover or progress to withstand cytokine storms. However, there is opportunity for global cooperation to advance scientific understanding of drug discovery and vaccine development. At the end of the day, human body of knowledge and resilience will prevail, and we shall pay tribute to those who could not see the end of this great pandemic.

REFERENCES
32. Habib H. Has Sweden’s controversial covid-19 strategy been successful. BMJ. 2020;369:m2376.
48. Kimball A, Hatfield KM, Arons M et al. Asymptomatic and Presymptomatic SARS-CoV-2 Infections in Residents of a Long-Term Care Skilled Nursing Facility - King County, Washington, March
52. An J, Liao X, Xiao T et al. Clinical characteristics of the recovered COVID-19 patients with re-detectable positive RNA test. 2020
77. Radzikowska U, Ding M, Tan G et al. Distribution of ACE2, CD147, CD26 and other SARS-CoV-2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID-19 risk factors. Allergy. 2020


